TRELEGY ELLIPTA approved in Canada

[gerald]

This was put out by the company that makes the inhaler. However, if anyone was waiting for the triple thereapy to be available, it is now approved.


--------------------------------------
TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD.


MISSISSAUGA, ON, April 5, 2018 /CNW/ - TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol), has been approved in Canada as the first and only inhaler product that combines three active molecules for the long-term, once daily, maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema in patients who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-adrenergic agonist.

TRELEGY ELLIPTA is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK's Ellipta dry powder inhaler.

TRELEGY ELLIPTA availability is expected this June.

Dr. Susie Barnes, VP and Country Medical Director for GSK in Canada, said "COPD is a progressive and debilitating lung disease that can worsen over time, and represents a significant burden to patients and healthcare systems. The addition of TRELEGY ELLIPTA to our portfolio of respiratory medicines is an important milestone for GSK, building on our long heritage in this area and our relentless drive to ensure the right treatment for the right patient."

"We are delighted that the long-standing collaboration between Innoviva and GSK to develop respiratory medicines that meet patient needs has led to the approval of TRELEGY ELLIPTA in Canada. This is a significant milestone as healthcare professionals now have a single inhaler triple therapy option to consider for their patients with COPD," said Dr. Theodore J. Witek Jr., Senior Vice President and Chief Scientific Officer of Innoviva, Inc.

www.newswire.ca/news-releases/trelegy-ellipta-approved-in-canada-as-the-first-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-678873943.html

[joany]

Very interesting.  I look forward to possibly reducing all the gyrations taking meds I go through first thing in the morning and last thing at night.